These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37170109)

  • 1. Glucocorticoid Receptor (GR) antagonism as disease-modifying treatment for MDD with childhood trauma: protocol of the RESET-medication randomized controlled trial.
    Linsen F; Broeder C; Sep MSC; Verhoeven JE; Bet PM; Penninx BWJH; Meijer OC; Vinkers CH
    BMC Psychiatry; 2023 May; 23(1):331. PubMed ID: 37170109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and rationale of the REStoring mood after early life trauma with psychotherapy (RESET-psychotherapy) study: a multicenter randomized controlled trial on the efficacy of adjunctive trauma-focused therapy (TFT) versus treatment as usual (TAU) for adult patients with major depressive disorder (MDD) and childhood trauma.
    Gathier AW; Verhoeven JE; van Oppen PC; Penninx BWJH; Merkx MJM; Dingemanse P; Stehouwer KMKS; van den Bulck CMM; Vinkers CH
    BMC Psychiatry; 2023 Jan; 23(1):41. PubMed ID: 36650502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eye movement desensitization and processing for adolescents with major depressive disorder: study protocol for a multi-site randomized controlled trial.
    Paauw CC; de Roos C; Koornneef MGT; Elzinga BM; Boorsma TM; Verheij MA; Dingemans AE
    Trials; 2023 Mar; 24(1):206. PubMed ID: 36941688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Childhood trauma dependent anxious depression sensitizes HPA axis function.
    Menke A; Lehrieder D; Fietz J; Leistner C; Wurst C; Stonawski S; Reitz J; Lechner K; Busch Y; Weber H; Deckert J; Domschke K
    Psychoneuroendocrinology; 2018 Dec; 98():22-29. PubMed ID: 30086534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression.
    Block T; Petrides G; Kushner H; Kalin N; Belanoff J; Schatzberg A
    J Clin Psychopharmacol; 2017 Oct; 37(5):505-511. PubMed ID: 28708736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
    Griebel G; Beeské S; Stahl SM
    J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized, double-blind, placebo-controlled, hybrid parallel-arm study of low-dose naltrexone as an adjunctive anti-inflammatory treatment for major depressive disorder.
    Plank JR; Glover SC; Moloney BD; Hoeh NR; Sundram F; Sumner RL; Muthukumaraswamy S; Lin JC
    Trials; 2022 Sep; 23(1):822. PubMed ID: 36175917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistent effects of mifepristone (RU-486) on cortisol levels in bipolar disorder and schizophrenia.
    Gallagher P; Watson S; Elizabeth Dye C; Young AH; Nicol Ferrier I
    J Psychiatr Res; 2008 Oct; 42(12):1037-41. PubMed ID: 18255098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial.
    Lieverse R; Van Someren EJ; Nielen MM; Uitdehaag BM; Smit JH; Hoogendijk WJ
    Arch Gen Psychiatry; 2011 Jan; 68(1):61-70. PubMed ID: 21199966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The roles of comorbidity and trauma exposure and its timing in shaping HPA axis patterns in depression.
    Mayer SE; Peckins M; Kuhlman KR; Rajaram N; Lopez-Duran NL; Young EA; Abelson JL
    Psychoneuroendocrinology; 2020 Oct; 120():104776. PubMed ID: 32593866
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, 12 month follow-up, placebo-controlled trial of mifepristone on cognition in alcoholics: the MIFCOG trial protocol.
    Donoghue K; Rose A; Coulton S; Milward J; Reed K; Drummond C; Little H
    BMC Psychiatry; 2016 Feb; 16():40. PubMed ID: 26912003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, placebo-controlled, crossover trial of mifepristone in Gulf War veterans with chronic multisymptom illness.
    Golier JA; Caramanica K; Michaelides AC; Makotkine I; Schmeidler J; Harvey PD; Yehuda R
    Psychoneuroendocrinology; 2016 Feb; 64():22-30. PubMed ID: 26600007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Childhood trauma predicts antidepressant response in adults with major depression: data from the randomized international study to predict optimized treatment for depression.
    Williams LM; Debattista C; Duchemin AM; Schatzberg AF; Nemeroff CB
    Transl Psychiatry; 2016 May; 6(5):e799. PubMed ID: 27138798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial.
    Hedayati SS; Gregg LP; Carmody T; Jain N; Toups M; Rush AJ; Toto RD; Trivedi MH
    JAMA; 2017 Nov; 318(19):1876-1890. PubMed ID: 29101402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and biological effects of mifepristone treatment for psychotic depression.
    Flores BH; Kenna H; Keller J; Solvason HB; Schatzberg AF
    Neuropsychopharmacology; 2006 Mar; 31(3):628-36. PubMed ID: 16160710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
    Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
    Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electroacupuncture plus moxibustion therapy for patients with major depressive disorder: study protocol for a randomized controlled trial.
    Kim M; Choi EJ; Kim SP; Kim JE; Park HJ; Kim AR; Seo BN; Kwon OJ; Cho JH; Chung SY; Kim JH
    Trials; 2017 Jan; 18(1):16. PubMed ID: 28086934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.